Objective:

To evaluate the efficacy and safety of renizgamglogene autogedtemcel (reni-cel) in increasing fetal hemoglobin levels in patients with severe sickle cell disease.

Key Findings:

• Total hemoglobin increased from 9.8 g/dL to 13.8 g/dL by six months.
• Fetal hemoglobin levels rose from 2.5% to 48.1%.
• 27 out of 28 patients experienced no severe vaso-occlusive events post-infusion.
• F-cell levels exceeded 99% by month 6.
• Neutrophil recovery median was 23 days and platelet recovery was 25 days.

Interpretation:

The CRISPR/Cas12a gene-editing technology shows potential for a functional cure in sickle cell disease, with significant increases in fetal hemoglobin and reduced vaso-occlusive events.

Limitations:

• The RUBY trial was terminated early, limiting the scope of findings.
• Safety findings were consistent with existing treatments but require further validation.

Conclusion:

These results support promoter editing as a promising strategy for fetal hemoglobin reactivation in sickle cell disease, potentially offering a new treatment avenue.